NCT04904614View on ClinicalTrials.gov

Letermovir Use in Heart Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

January 14, 2025

Study Completion Date

January 14, 2025

Conditions
Cytomegalovirus DiseaseCytomegalovirus InfectionsHeart Transplant InfectionAntiviral ToxicityNeutropenia
Interventions
DRUG

Letermovir

Open label trial of the licensed drug, letermovir, in a population of heart transplant recipients for which it is not yet licensed

Trial Locations (1)

02111

Tufts Medical Center, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Tufts Medical Center

OTHER

NCT04904614 - Letermovir Use in Heart Transplant Recipients | Biotech Hunter | Biotech Hunter